Articles On Neuren Pharmaceuticals (ASX:NEU)

The US Food and Drug Administration (FDA) approves Neuren Pharmaceuticals’ (NEU) North American partner’s trofinetide drug as a treatment for Rett syndrome Trofinetide, marketed under the brand name DAYBUE, is now the first drug approved...

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is starting the week very positively. In morning trade, the ASX All Ords biotech company’s shares are up 27% to a multi-year high of $9.74. Why is the ASX All Ords biotech stock jumpi...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Neuren’s compound trofinetide has been granted US FDA approval for the treatment of Rett’s syndrome Trofinetide has been given brand name DAYBUE and is expected to be available in the US by end of April 2023 Healthcare analysts welcome ne...

ASX health stocks fall 1.87% in the past five days as reporting season ends Healius moves to a statutory loss of ~$29 million following reduced demand for Covid-19 testing Catalysts in next few months for several ASX health stocks which co...

Neuren Pharmaceuticals (ASX:NEU) has announced the appointment of Joe Basile as an independent non-executive director.

The US FDA is expected to decide on March 12 whether it approves Neuren’s trofinetide for Rett’s syndrome If the drug is approved it will be a game-changer financially for the biotech Australia has had only a few FDA approvals for drugs/d...

Neuren Pharmaceuticals (ASX:NEU) has announced that the US FDA has reviewed Neuren’s Investigational New Drug application for NNZ-2591 in Prader-Willi syndrome.

Cynata Therapeutics’ chief medical officer, Jolanta Airey, gives a step-by-step guide on what biotechs need to do to commence a clinical trial Which ASX biotechs have an IND submission to the FDA and will start a clinical trial soon?   Wh...

Universal Bio completes patient recruiting for Xprecia Prime study Neuren Pharma given approval by FDA to start Phase 2 trial Chimeric completes Phase 1A trial with flying colours   Universal Bio to lodge FDA submission this quarter Unive...

Neuren Pharmaceuticals (NEU) receives the green light to go ahead with a phase two clinical trial testing its NNZ-2591 drug on children with Prader-Willi syndrome It comes after the company applied for investigational new drug approval f...

ASX health stocks rise 4.6% this week with positive signs of being back in favour Volpara soars after announcing its first net cash flow positive quarter Morgans basket of healthcare stock picks for 2023 faring well,  all up YTD Healthca...

The All Ordinaries Index (ASX: XAO) is back in the green on Wednesday, driven higher by four shares leaping to new 52-week highs. Right now, the All Ordinaries Index is up 0.12%, trading at 7,606.9 points. Let’s take a closer look at fou...

The S&P/ASX 300 Index (ASX: XKO) is full of interesting businesses. A leading fund manager has picked out two lower-profile ASX 300 shares that could do well. Wilson Asset Management (WAM) operates a number of listed investment compani...

2023 off to a bit of a dismal start, down 1.3% on the opening day of trade GreenX soaring after rumblings from Poland over $1.3 billion payday Chinese markets gain before the rest of the trading world gets back from holidays   For about 1...

The ASX tumbled over 1% in the first trading day of 2023 Stocks were sold across all sectors, with some blaming lack of liqudity Properties across all Australia fell again in December   It wasn’t the start of year investors had wanted to...

The new year is off to a disastrous start for the All Ordinaries Index (ASX: XAO) and most of the shares that call it home. Despite posting a strong start to Tuesday’s session ­– it jumped as high as 0.47% in early trade – the bench...

Highlights The ASX 200 benchmark index closed in the red today (December 28), losing 32.30 points or 0.45% to end at 7,075.40 points. Over the last five days, the index has lost 0.56% and 4.65% over the last 52 weeks. Healthcare was t...

Good news is bad news for the US economy Aussie benchmark goes deep into a pre-Christmas shame spiral Ho ho oh s%#$! What just happened?   The Closing Jingle Bell has rung, so that’s it until after Christmas for 2022! What a pity today’s...

Neuren Pharmaceuticals (NEU) submits an investigational new drug (IND) application for its NNZ-2591 treatment for Prader-Willi syndrome The new IND was submitted to the US Food and Drug Administration (FDA) on December 22 for approval to...

Warrego Energy puts out initial substantial shareholder notice for Gina Rinehart entities following takeover bid Whitehaven Coal finishes November with a new substantial shareholder as two of its directors sell down holdings Neuren Pharma...

ASX Health sector is continuing its upward trend, marginally up this week 0.87%  Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

The All Ordinaries Index (ASX: XAO) is kicking off this Tuesday’s session on a very positive note so far. At the time of writing, the All Ords has gained a healthy 0.4%, putting it back over 7,375 points. But for some ASX all Ords shares,...

The All Ordinaries Index (ASX: XAO) is down in the dumps on Thursday. But not all shares that call the benchmark index home are trading in the red. These three have defied the sell-off to trade at their highest points in years. Right now,...

Neuren Pharmaceuticals (NEU) receives a US$10 million (A$16 million) milestone payment from its partner, Acadia PharmaceuticalsThe payment follows the US FDA’s acceptance for review of Acadia’s new drug application for trofinetide, which wo...

Neuren Pharmaceuticals (ASX:NEU) has received the milestone payment of US$10 million from its US partner Acadia Pharmaceuticals.

Welcome back class to Part 2 of our Clinical Trials 101. When it comes to healthcare and life sciences investing there is one area where investors should take notice and that is research and clinical trials.  An understanding of how the tri...

The S&P/ASX 200 Index (ASX: XJO) is having a day to forget on Wednesday. In afternoon trade, the benchmark index is down 2.4% to 6,843.4 points. Four ASX shares that have managed to avoid the selloff and push higher today are listed...

The S&P/ASX 200 Index (ASX: XJO) is on form again on Tuesday. In afternoon trade, the benchmark index is up 0.7% to 7,010.9 points. Four ASX shares that are climbing more than most today are listed below. Here’s why they are pushing...

Neuren Pharmaceuticals (NEU) receives priority review for a New Drug Application (NDA) of its trofinetide drug for the treatment of Rett syndromeThe US Food and Drug Administration (FDA) granted the priority review and also assigned a Presc...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

The All Ordinaries Index (ASX: XAO) has been in a pendulum swing over the ASX reporting season. Here are three ASX healthcare companies that have gone under the radar. Regis Healthcare Ltd (ASX: REG) The Regis share price only lifted 0.3...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Several ASX health stocks have...

Neuren Pharmaceuticals (ASX:NEU) has announced its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome and Pitt Hopkins syndrome are open for enrolment.

Neuren Pharmaceuticals (ASX:NEU) has announced its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome and Pitt Hopkins syndrome are open for enrolment.

Highlights Neuren Pharmaceuticals (ASX:NEU) has began recruiting subjects for Phase 2 clinical trials of its second drug candidate, NNZ-2591. The trials will be conducted in children each for Pitt Hopkins syndrome (PTHS) and Phelan-McD...

Highlights Neuren Pharmaceuticals (ASX:NEU) has began recruiting subjects for Phase 2 clinical trials of its second drug candidate, NNZ-2591. The trials will be conducted in children each for Pitt Hopkins syndrome (PTHS) and Phelan-McD...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

Neuren Pharmaceuticals (NEU) opens enrolment for phase two neurological clinical trials of its drug candidate NNZ-2591 The study is for children with Phelan-McDermid syndrome (PMS) and Pitt Hopkins syndrome (PTHS), with the first trials sc...

Highlights:  WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 countries sofar. In Australia, so far, 44 confirmed cases of Monkeypox have been confirmed. Monkeypox is a disease that causes rash turning...

Highlights:  WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 countries sofar. In Australia, so far, 44 confirmed cases of Monkeypox have been confirmed. Monkeypox is a disease that causes rash turning...

Highlights The Australian share market ended on a positive note on Wednesday. The ASX 200 advanced 23%, or 15.90 points to end at 6,823.20 points. The ASX All Ordinaries index finished 0.18%, or90 points higher, to close at...

Highlights The Australian share market ended on a positive note on Wednesday. The ASX 200 advanced 23%, or 15.90 points to end at 6,823.20 points. The ASX All Ordinaries index finished 0.18%, or90 points higher, to close at...

The All Ordinaries Index (ASX: XAO) is down a slender 0.04% in late afternoon trading, having made up some larger earlier losses following the release of Australia’s latest inflation figures. Within the index of top 500 stocks, three ASX...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Pac Partners...

A major milestone for Australian company Neuren Pharmaceuticals (ASX:NEU) with its US partner Acadia submitting trofinetide to the FDA for the treatment of Rett syndrome.

Neuren Pharmaceuticals (NEU) submits a new drug application (NDA) to the US FDA for its Rett syndrome treatment through its partner, Acadia Pharmaceuticals If the NDA is approved by the FDA, Neuren expects to earn revenue over 2022 and 202...

HeraMED’s device is effective for telemedicine in monitoring pregnant women Mesoblast issues strong study results OncoSil announces success in Spain Just-released results from a clinical trial undertaken by Israel’s Sheba Medical Center c...